121 related articles for article (PubMed ID: 8252036)
1. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
Kaul R; Gao GP; Balamurugan K; Matalon R
Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
[TBL] [Abstract][Full Text] [Related]
2. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
Bitto E; Bingman CA; Wesenberg GE; McCoy JG; Phillips GN
Proc Natl Acad Sci U S A; 2007 Jan; 104(2):456-61. PubMed ID: 17194761
[TBL] [Abstract][Full Text] [Related]
3. Human induced pluripotent stem cell line (SDQLCHi064-A) derived from a patient with Canavan disease carrying c.556_559dup GTTC and c.919delA mutations in the ASPA gene.
Liu N; Ge Y; Yang Y; Zhao F; Lv Y; Li Z; Dong R; Liu Y; Gai Z
Stem Cell Res; 2024 Apr; 76():103325. PubMed ID: 38309148
[TBL] [Abstract][Full Text] [Related]
4. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
[TBL] [Abstract][Full Text] [Related]
5. Canavan's spongiform leukodystrophy (Aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature.
Rossler L; Lemburg S; Weitkämper A; Thiels C; Hoffjan S; Nguyen HP; Lücke T; Heyer CM
J Ultrasound; 2023 Dec; 26(4):757-764. PubMed ID: 35187608
[TBL] [Abstract][Full Text] [Related]
6. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
7. On Clustering of Juvenile Canavan disease in an Indian community due to population bottleneck and isolation: Genomic signatures of a founder event.
Das R
Eur J Hum Genet; 2023 Jan; 31(1):7-8. PubMed ID: 36316492
[No Abstract] [Full Text] [Related]
8. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.
Kaul R; Gao GP; Matalon R; Aloya M; Su Q; Jin M; Johnson AB; Schutgens RB; Clarke JT
Am J Hum Genet; 1996 Jul; 59(1):95-102. PubMed ID: 8659549
[TBL] [Abstract][Full Text] [Related]
9. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome).
Matthijs G; Schollen E; Pardon E; Veiga-Da-Cunha M; Jaeken J; Cassiman JJ; Van Schaftingen E
Nat Genet; 1997 May; 16(1):88-92. PubMed ID: 9140401
[TBL] [Abstract][Full Text] [Related]
10. Deep mutational scanning reveals a correlation between degradation and toxicity of thousands of aspartoacylase variants.
Grønbæk-Thygesen M; Voutsinos V; Johansson KE; Schulze TK; Cagiada M; Pedersen L; Clausen L; Nariya S; Powell RL; Stein A; Fowler DM; Lindorff-Larsen K; Hartmann-Petersen R
Nat Commun; 2024 May; 15(1):4026. PubMed ID: 38740822
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.
Grønbæk-Thygesen M; Hartmann-Petersen R
Cell Biosci; 2024 Apr; 14(1):45. PubMed ID: 38582917
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation.
Corti M; Byrne BJ; Gessler DJ; Thompson G; Norman S; Lammers J; Coleman KE; Liberati C; Elder ME; Escolar ML; Tuna IS; Mesaros C; Kleiner GI; Barbouth DS; Gray-Edwards HL; Clement N; Cleaver BD; Gao G
Mol Ther Methods Clin Dev; 2023 Sep; 30():303-314. PubMed ID: 37601414
[TBL] [Abstract][Full Text] [Related]
13. Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice.
Fröhlich D; Kalotay E; von Jonquieres G; Bongers A; Lee B; Suchowerska AK; Housley GD; Klugmann M
Front Mol Neurosci; 2022; 15():1061257. PubMed ID: 36568275
[TBL] [Abstract][Full Text] [Related]
14. Preclinical biodistribution, tropism, and efficacy of oligotropic AAV/Olig001 in a mouse model of congenital white matter disease.
Francis JS; Markov V; Wojtas ID; Gray S; McCown T; Samulski RJ; Figueroa M; Leone P
Mol Ther Methods Clin Dev; 2021 Mar; 20():520-534. PubMed ID: 33614826
[TBL] [Abstract][Full Text] [Related]
15. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.
Feng L; Chao J; Tian E; Li L; Ye P; Zhang M; Chen X; Cui Q; Sun G; Zhou T; Felix G; Qin Y; Li W; Meza ED; Klein J; Ghoda L; Hu W; Luo Y; Dang W; Hsu D; Gold J; Goldman SA; Matalon R; Shi Y
Adv Sci (Weinh); 2020 Dec; 7(23):2002155. PubMed ID: 33304759
[TBL] [Abstract][Full Text] [Related]
16. The CNS Myelin Proteome: Deep Profile and Persistence After Post-mortem Delay.
Jahn O; Siems SB; Kusch K; Hesse D; Jung RB; Liepold T; Uecker M; Sun T; Werner HB
Front Cell Neurosci; 2020; 14():239. PubMed ID: 32973451
[TBL] [Abstract][Full Text] [Related]
17. Gene Delivery to Nonhuman Primate Preimplantation Embryos Using Recombinant Adeno-Associated Virus.
Wang D; Niu Y; Ren L; Kang Y; Tai PWL; Si C; Mendonca CA; Ma H; Gao G; Ji W
Adv Sci (Weinh); 2019 Nov; 6(21):1900440. PubMed ID: 31728271
[TBL] [Abstract][Full Text] [Related]
18. First Record Mutations in the Genes
Froukh T
Biomed Res Int; 2019; 2019():7235914. PubMed ID: 30834272
[TBL] [Abstract][Full Text] [Related]
19. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
